Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/99069
Title: | Key challenges for next‐generation pharmacogenomics |
Authors: | Kampourakis, Kostas Vayena, Effy Mitropoulou, Christina Schaik, Ron H. Cooper, David N. Borg, Joseph J. Patrinos, George P. |
Keywords: | Pharmacogenomics Genomics -- Case studies Molecular genetics Nucleotides -- Synthesis |
Issue Date: | 2014 |
Publisher: | EMBO |
Citation: | Kampourakis, K., Vayena, E., Mitropoulou, C., van Schaik, R. H., Cooper, D. N., Borg, J., & Patrinos, G. P. (2014). Key challenges for next‐generation pharmacogenomics: Science & Society series on Science and Drugs. EMBO Reports, 15(5), 472-476. |
Abstract: | The “post-genomic revolution” has advanced our understanding of the molecular etiology of a range of human genetic diseases, which might lead to improved disease prognosis and treatment. Over the past decade, genomics research has revealed the genomic variants underlying diseases, from single nucleotide variations to complex genome rearrangements, and/or altered gene expression patterns that lead directly to pathogenesis. These findings have enormous potential to guide physicians in their task of estimating disease risk and deciding on the most efficient and safe treatment options. More generally, genomic research could catalyze the maturation of individualized healthcare by considering each person’s genomic profile alongside his or her clinical condition to personalize therapeutic interventions. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/99069 |
Appears in Collections: | Scholarly Works - FacHScABS |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Key_challenges_for_next_generation_pharmacogenomics.pdf Restricted Access | 333.65 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.